Fidia Farmaceutici, SpA
http://www.fidiapharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fidia Farmaceutici, SpA
Bayer's Bets In Parkinson's Start To Bear Fruit
The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.
BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs
There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.
Akero Shows More Strong Fibrosis Data, But Analysts Cite Safety Worry
Akero is developing weekly injectable efruxifermin for MASH with solid 96-week efficacy data and three Phase III studies underway. But will it find a treatment niche in a competitive space?
EASL: Sagimet Pill Is Overlooked But Could Make A Splash In MASH
While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Bioos
- Fidia Pharma Group
- Glaucoom
- OftaH.T. e Neoox
- Soluciones Bioregenerativas SL
- Sooft Italia
- Fidia Pharma Austria GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice